A product label can state a purity figure. A Certificate of Analysis, or COA, should show where that figure came from, which batch it relates to and how the material was assessed. For buyers comparing research peptides, this certificate of analysis guide sets out what meaningful batch documentation looks like, what it can verify and where caution is still required.
A COA is not a marketing badge. It is a technical record tied to a defined material and, ideally, a defined production batch. When a supplier makes quality-led claims around compounds such as BPC-157, GHK-Cu, MOTS-C, NAD+ or Retatrutide, the supporting document should be clear enough to inspect rather than simply treated as a reassuring image.
What a Certificate of Analysis Is Designed to Show
A Certificate of Analysis records the results of specified tests against a product specification. In peptide supply, its central purpose is to demonstrate that the batch tested corresponds to the named compound and meets the stated quality criteria, commonly including identity and chromatographic purity.
The distinction between a specification and a result matters. A specification may state that a peptide must meet a purity threshold of 99% or above. The result is the measured figure for that particular lot. A credible COA presents both, so the reader can see whether the batch passed the stated requirement rather than relying on a broad product-level claim.
For research materials, a COA should support sensible purchasing decisions, traceability and consistent handling. It does not turn a research-use compound into a medicinal product, nor does it establish suitability for human use. The scope of the document needs to be read as carefully as the numbers on it.
The First Check: Product and Batch Traceability
Start with the identifiers. The product name should match the item being considered, including the relevant salt, ester, conjugate or format where applicable. Small differences can matter. A COA for one peptide form should not be assumed to cover another simply because the names appear similar.
The batch or lot number is the most useful traceability point. It should match the number shown on the vial, product packaging or associated batch record. If a supplier displays one generic certificate across multiple batches without a clear batch connection, it provides far less assurance than a batch-specific report.
Check the declared quantity, where listed, and the analysis or release date. A date alone does not make a document current or invalid, but it helps establish when the testing was performed. For products held over longer periods, storage conditions and product stability become relevant considerations alongside the original result.
A useful COA will usually include the following details:
- the product name and a unique batch or lot number;
- the test date, report date or release date;
- the analytical methods used and their stated results;
- acceptance criteria or specifications for each test; and
- laboratory or quality-control authorisation details.
Identity: Confirming the Material Is What It Claims to Be
Identity testing addresses a basic but essential question: is the analysed material consistent with the stated peptide? For peptides, mass spectrometry is widely used to confirm molecular mass. A COA may show a theoretical mass alongside an observed mass, often expressed in daltons.
The two values should be suitably close within the method’s expected tolerance. The precise interpretation depends on the instrument, charge state and reporting convention, so buyers do not need to overread a minor numerical difference. What matters is that the report states the test clearly and the outcome meets the acceptance criterion.
For more complex compounds or modified peptides, identity confirmation may need more than one technique. A mass result alone can be persuasive, but it does not describe every possible structural feature or impurity. This is why identity and purity should be considered together, not as interchangeable claims.
Purity: Understanding HPLC Results
High-performance liquid chromatography, usually shortened to HPLC, is one of the most familiar methods on peptide COAs. It separates components in a sample and reports the relative area of the main peak. A reported purity of 99% or higher generally indicates that the principal component accounted for at least that proportion under the stated chromatographic method.
This is valuable information, but it has limits. HPLC purity is method-dependent. The column, solvent system, wavelength and integration settings all influence the result. A COA that identifies the method and gives a clear purity result is more informative than one that simply prints “99% purity” without context.
Where a chromatogram is supplied, look for a dominant main peak and sensible reporting. A clean-looking graph is not enough on its own, since image quality, scaling and integration can affect appearance. The numerical result, method description and batch details remain the main points to assess.
Purity is also not the same as potency, sterility, endotoxin status or suitability for a particular application. A 99% HPLC result does not answer every quality question. It answers a specific analytical question about the composition of the tested sample.
Test Panels Depend on the Compound and Format
There is no single universal COA panel for every research compound. The right testing approach depends on the material, its formulation and the risks relevant to its intended laboratory handling.
For lyophilised peptide vials, identity and HPLC purity are often the primary buyer checks. Moisture content, residual solvents, peptide content, appearance or solubility may also be relevant, depending on the product and the manufacturer’s release specification. For copper peptides such as GHK-Cu, elemental composition or compound-specific testing may provide useful additional context.
For products supplied in a pen format, documentation should correspond to the finished presentation rather than only to a bulk input material. Identity and assay of the active material are still relevant, but so are the lot details for the finished unit and any testing claimed for that specific format. A certificate for an ingredient does not automatically validate every aspect of a finished product.
Similarly, bacteriostatic water and other ancillary laboratory materials require their own appropriate documentation. A peptide COA cannot be used as evidence for a separate diluent or accessory, even when both are supplied by the same retailer.
How to Spot Weak or Misleading Documentation
Poor documentation often relies on appearance rather than traceability. A heavily branded certificate with no batch number, no test method and no named laboratory provides limited practical value. The same applies to a report with results but no specifications, as there is no stated basis for pass or fail.
Be cautious where the product name is vague, the batch date predates the supplier’s current stock without explanation, or obvious fields have been edited. A laboratory logo is not, by itself, evidence that a laboratory performed the stated work. Consistency across the document is more useful than design polish.
It is also reasonable to ask whether the certificate relates to the batch being supplied. Responsible suppliers should be able to maintain a clear connection between product stock and supporting analysis. This is particularly relevant when repeat purchases are made over time, as a new lot may have a different test result even when the product specification remains unchanged.
A Practical Certificate of Analysis Guide for Buyers
Use the COA as one part of a wider supplier assessment. First, confirm that the product and batch identifiers align. Next, check that identity and purity results are shown against clear specifications. Then consider whether the testing is appropriate for the compound and format being purchased.
After that, assess the supplier’s overall quality controls. Clear research-use positioning, consistent product information, proper packaging, responsive batch documentation and dependable fulfilment all contribute to confidence. Fast tracked delivery is useful, particularly for planned research schedules, but it should complement product traceability rather than replace it.
At Biochemi, the value of batch-level analysis is straightforward: buyers should be able to assess the quality basis for the specific material they order. The strongest purchasing decision is not based on a purity claim alone. It is based on a certificate that connects the claim, the method and the batch in a way that can be checked.